New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
07:13 EDTCTIXCellceutix clinical trial of anti-cancer drug Kevetrin entering eighth cohort
Cellceutix reports that the safety committee overseeing the Phase 1 clinical trial evaluating Cellceutix's lead anti-cancer drug Kevetrin for solid tumors being conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has approved dosing for the eighth cohort. The dosing has been increased approximately 33% from the seventh cohort to 215 mg/m2. Enrollment for the eighth cohort is expected to commence shortly. Cellceutix would also like to inform shareholders that enrollment in the Phase 2b clinical trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections is approximately 70% complete. To date, no drug-related serious adverse events have been reported. The Company has been advised that the Brilacidin safety committee meeting is scheduled for the end of June. Cellceutix anticipates providing shareholders with an update on data from the trial and any commentary from the safety committee in the first half of July.
News For CTIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
14:26 EDTCTIXCellceutix meets with FDA for Phase 2 trial of Kevetrin for ovarian cancer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use